Canadian Guidelines for the Management of Plaque Psoriasis: Overview

  • Kim Papp
    From K. Papp Clinical Research, Waterloo, ON; Probity Medical Research, Waterloo, ON; Newlab Clinical Research Inc., St. John's, NL; Memorial University, St John's, NL; Lynderm Research Inc., Markham, ON; University of Toronto, Toronto, ON; Centre Dermatologique du Québec, Métropolitain, Québec, QC; Université Laval, Québec, QC; and SCRIPT, Toronto, ON
  • Wayne Gulliver
    From K. Papp Clinical Research, Waterloo, ON; Probity Medical Research, Waterloo, ON; Newlab Clinical Research Inc., St. John's, NL; Memorial University, St John's, NL; Lynderm Research Inc., Markham, ON; University of Toronto, Toronto, ON; Centre Dermatologique du Québec, Métropolitain, Québec, QC; Université Laval, Québec, QC; and SCRIPT, Toronto, ON
  • Charles Lynde
    From K. Papp Clinical Research, Waterloo, ON; Probity Medical Research, Waterloo, ON; Newlab Clinical Research Inc., St. John's, NL; Memorial University, St John's, NL; Lynderm Research Inc., Markham, ON; University of Toronto, Toronto, ON; Centre Dermatologique du Québec, Métropolitain, Québec, QC; Université Laval, Québec, QC; and SCRIPT, Toronto, ON
  • Yves Poulin
    From K. Papp Clinical Research, Waterloo, ON; Probity Medical Research, Waterloo, ON; Newlab Clinical Research Inc., St. John's, NL; Memorial University, St John's, NL; Lynderm Research Inc., Markham, ON; University of Toronto, Toronto, ON; Centre Dermatologique du Québec, Métropolitain, Québec, QC; Université Laval, Québec, QC; and SCRIPT, Toronto, ON
  • John Ashkenas
    Committee for the Canadian Psoriasis Guidelines

Description

<jats:p> New clinical treatment guidelines for plaque psoriasis, written by a panel of 16 Canadian dermatologists, were recently published online. These Canadian Guidelines for the Management of Plaque Psoriasis are evidence based and free of any influence from corporate sponsors and have been endorsed by the Canadian Dermatology Association (CDA). The Guidelines offer treatment recommendations for mild and moderate to severe body psoriasis, as well as for psoriasis affecting specific areas of the skin, such as the facial, flexural, and genital areas; nails; scalp; and palms and soles. The present overview describes the genesis and contents of the Guidelines, which are available in full through the CDA at (English) or (French). </jats:p>

Journal

Citations (1)*help

See more

Report a problem

Back to top